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Summary 
Interleukin  6  (IL-6)  is  considered an  important  mediator of acute  inflammatory responses. 
Moreover, IL-6 functions as  a differentiation and growth factor of hematopoietic precursor 
cells, B cells, T cells, keratinocytes, neuronal cells, osteoclasts,  and endothelial cells. IL-6 exhib- 
its its action via a receptor complex consisting of a specific IL-6 receptor (IL-6R) and a signal 
transducing subunit  (gp130).  Soluble forms  of both receptor components are  generated by 
shedding and are found in patients with various diseases such as acquired immune deficiency 
syndrome, rheumatoid arthritis, and others. The function of the soluble (s)IL-6R in vivo is un- 
known. Since human (h)IL-6 acts on human and murine target cells, but routine IL-6 on mu- 
rine cells only, we constructed transgenic mice expressing the hslL-6R. We report here that in 
the presence of hslL-6R,  mice are hypersensitized towards hlL-6, mounting an acute phase 
protein gene induction at significantly lower IL-6 dosages  compared to control animals.  Fur- 
thermore, in hslL-6R transgenic mice, the detected acute phase response persists  for a longer 
period of time. The IL-6/IL-6R complex prolongs markedly the IL-6 plasma half-life. Our re- 
sults reinforce the role of the hslL-6R as an agonistic protein, help to understand the function 
of the hslL-6R in vivo, and highlight the significance of the receptor in the induction of the 
acute phase response. 
I 
L-6 is a multifunctional cytokine and plays a central role 
.as  a differentiation and growth factor of hematopoietic 
precursor cells, B cells, T cells, keratinocytes, neuronal cells, 
osteoclasts, and endothelial cells (for reviews see references 
1  and 2).  Moreover, IL-6 modulates  the  transcription  of 
several liver-specific genes during acute inflammatory states 
(3). Altered IL-6 serum levels have been described in sev- 
eral hematological diseases such as plasmacytoma or Castle- 
man's disease  (4,  5), mesangial glomemlonephritis (6),  os- 
teoporosis (7),  cachexia (8), rheumatoid arthritis (9), sepsis 
(10,  11), and AIDS (12,  13). 
IL-6 exhibits its action on target cells by acting through a 
receptor complex consisting of a specific IL-6-binding pro- 
tein (IL-6R) and a signal-transducing subunit (gp130). The 
IL-6/IL-6R complex induces the homodimerization of two 
gp130  molecules leading to a number of intracellular sig- 
naling events including activation of the transcription factor 
NF-IL-6,  probably  via  the  Ras-microtubulus-associated 
protein kinase cascade (14),  and activation of the Janus ki- 
nase/signal transducer and activator of transcription signal- 
ing pathway (15-17). 
Soluble forms of the IL-6R (sIL-6R)  1 and gpl30 (sgp130) 
are found in different body fluids and their concentrations 
may be elevated in patients with various inflammatory dis- 
eases  such  as AIDS  and rheumatoid arthritis  (13,  18-20). 
They are generated by limited proteolysis and are released 
from the cell surface (21-23). It has also been demonstrated 
that an IL-6R mRNA lacking the coding sequence for a 
transmembrane  domain  exists.  This  mRNA  presumably 
derives from a differential splicing event and can lead to the 
synthesis of a sIL-6R protein (24).  The sIL-6R retains its 
ligand-binding capacity (25, 26) and associates with sgpl30 
in the presence of IL-6 (23,  27). In vitro experiments have 
demonstrated  that  in  contrast  to  other  soluble  receptors, 
such as the receptors for IL-1 or TNF, which are known to 
1Abbreviations used in this paper: hslL-6R, human soluble IL-6R; PEPCK, 
phosphoenolpyruvate  carbox'ykinase;  sIL-6R, soluble IL-6R. 
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cally  on  cells  that  express  gp130.  Most  recently,  it  was 
shown that heart muscle cells respond to IL-6 only in the 
presence  of the  slL-6R  (29).  By  this  transsignaling  path- 
way, slL-6R is able to activate target cells  that express only 
gp130 molecules on their cell surface but lack membrane- 
bound IL-6R (30). 
Despite  the in vitro studies  cited above and the finding 
that soluble forms oflL-6R and gp130 are found in various 
diseases,  the function of these soluble proteins in vivo is not 
understood.  The species specificity of IL-6, which acts on 
human and murine  cells,  whereas routine  IL-6 is only ac- 
tive  on murine  cells,  was the basis  to construct transgenic 
mice expressing the human slL-6R (hslL-6R) to study the 
role of the hslL-6R in vivo without the confounding effect 
of endogenous  routine  IL-6.  Here  we  demonstrate  that 
upon injection of human IL-6, transgenic  mice expressing 
the  hsIL-6R, are  hypersensitized  towards  the  IL-6-medi- 
ated acute phase response. Moreover, hslL-6R functions as 
a carrier protein for its ligand, thereby markedly prolonging 
the plasma half-life of IL-6. 
Materials and Methods 
Chemicals.  Protein  A-Sepharose  CL-4B was  obtained  from 
Pharulacia  (Freiburg,  Germany). DMEM, MEM, and penicillin/ 
streptomycin were from Gibco (Eggenstein,  Germany). FCS was 
from Seromed (Berlin,  Germany). The preparation of the mono- 
specific  antiserum against  IL-6R was  described previously (26). 
Recombinant human  and recombinant murine  IL-6 were pre- 
pared as described (3l, 32). cx-[32p]dATP  (110 TBq/mmol) was from 
Amersham International  (Amersham, Bucks, UK). The anti-IL-6R 
mAb MT18 was kindly supplied  by Dr. K. Yasukawa (TOSOH 
Corp., Tokyo, Japan).  The rabbit IgG anti-mouse antibody was 
obtained from Dako  (Hamburg,  Germany).  The  hlL-6 ELISA 
kit  was obtained  from CLB (Amsterdam,  The Netherlands).  The 
hlL-6R_ ELISA kit was from Seromed (Giel3en, Germany). 
Generation of Phosphoenolpyruvate Carboxykinase (PEPCK)/hlL-6 
Transgenic Mice.  A 1.1-kb cDNA fragment coding for the extra- 
cellular  part of hlL-6R was amplified  by PCR and cloned into 
the Sall site of the pTZ18R vector. A 530-bp EcoRI-BgllI DNA 
fragment of the mouse PEPCK promoter  (33) was  cloned up- 
stream  from the hlL-6R cDNA. A BamHI site was inserted  up- 
stream  the PEPCK promotor.  A  1.2-kb DNA fragment corre- 
sponding to  the  3'  portion  of the  human  13-globin gene  (34) 
followed by a poly-A site was inserted  downstream from the hlL- 
6R cDNA between the SalI and the HindlII sites of the vector. 
The  BamHI-BamHI fragment  containing  the  entire  construct 
(see Fig. 1 A) was gel purified and microinjected into the pronu- 
clei  of fertilized  eggs of NMRI and B602F~ mice.  Mice  were 
screened for the presence ofhlL-6R by Southern blot of EcoRI- 
HindlII-digested tail DNA. 
Animal Treatment.  Mice were maintained in a 12-h light--dark 
cycle under standard conditions and were provided with food and 
water ad libitum.  Procedures involving animals and their care were 
conducted in conformi  W with national and international laws and 
policies,  rhlL-6 was injected intraperitoneally  at doses indicated 
in the figures. 
RNA Expression.  Mice were killed by cervical dislocation  and 
R.NA was isolated  from different  organs  by the phenol/chloro- 
form method (35) and subjected to Northern blot analysis. 5 Ixg 
of  heat-denatured RNA per sample was fractionated  on a 1% aga- 
rose gel with 7% formaldehyde. The separated  RNA was trans- 
ferred  to  GeneScreen  Plus  membranes  (DuPont-New  England 
Nuclear, Dreieich, Germany) according to the supplier's  instruc- 
tions. The filters were prehybridized at 68~  for 2 h in 10% dex- 
tran sulfate, 1 M NaC1, 1% SDS, and hybridized in the same solu- 
tion with 32p-cDNA fragments  labeled  by random priming (36). 
The following probes were used: a 0.9-kb Hinfl restriction  frag- 
ment of human haptoglobin cDNA and a 1.2 PstI-XhoI restric- 
tion fragment ofhlL-6R cDNA. 
Serum IL-6 Measurements and Cell Growth.  Blood was drawn by 
cardiac  punction under general  anesthesia  of the mice. A  hlL-6 
ELISA was  performed  according to  the  supplier's  instructions. 
For  the  murine  B9  proliferation  assay, murine  serum  samples 
were serially diluted.  The assay was performed as described  (37). 
One B9 unit corresponding to N1 pg hlL-6/ml led to half-maxi- 
mal proliferation  of B9 cells. Cells were grown in DMEM at 5% 
CO  2 in a water-saturated atmosphere. All cell culture media were 
supplemented with 10% FCS, 100 rag/liter streptomycin, and 60 
rag/liter penicillin. 
Serum IL-6/hslL-6R  Complex and IL-6R  Immunoprecipitation. 
100 p~l ofmurine serum was preincubated with 100 Ixl of protein 
A-Sepharose (20 mg/ml) and 800 Ixl ofPBS/0.01% Tween for 2 h 
at 4~  After centrifugation,  the supernatant was incubated  with the 
monoclonal anti-IL-6R antibody MT18 for 4 h at 4~  Immune 
complexes were precipitated  with  100  txl protein  A-Sepharose 
for 2 h at 4~  separated  by 12.5% SDS-PAGE, and subjected to 
Western blot analysis using a polyclonal specific antiserum  against 
hlL-6R as previously described  (26). 
Results 
Generation of PEPCK/hslL-6R Transgenic Mice.  To  drive 
expression of the hslL-6R in the liver oftransgenic mice, we 
used  the  promoter  of the  mouse  PEPCK gene,  which  is 
neonatal and thereby permits one to evaluate the influence of 
gene products after birth (33).  The promoter has been shown 
to  be  specific for liver and kidney  (38).  DNA  (Fig.  1 A) 
was microinjected into the pronuclei of fertilized eggs from 
NMRI  mice.  Four  PEPCK/hslL-6R  transgenic  founders 
were obtained and verified by Southern blot analysis. Mice 
were  interbred  to  obtain  homozygous and  heterozygous 
transgenic PEPCK/hslL-6R mice. 
Characterization of PEPCK/hslL-6R Transgenic  Mice.  Tail 
DNA was digested with EcoRI/HindlII and used for South- 
ern blot analysis (Fig.  1 B). In homozygous mice,  the level 
of the transgene was twofold of that observed in heterozy- 
gous  mice.  As  can  be  seen  in  Fig.  1  C,  the  hslL-6R- 
mRNA  levels  in  homozygous  mice  were  significantly 
higher than those observed in heterozygous mice. Accord- 
ingly, in immunoprecipitation experiments, the highest levels 
of hslL-6R were detected in homozygous mice (Fig.  1 D). 
Transgenic mice expressed the shlL-6R in the low micro- 
gram range as determined by ELISA (data not shown). When 
Northern blot analysis was performed with RNA from dif- 
ferent mouse tissues,  hslL-6R-mRNA was detected in the 
liver and  kidney,  but  not in heart,  muscle,  or brain  (data 
not shown). 
hlL-6 Does Not Influence the Expression ofhslL-6R.  To ex- 
clude the possibility that hlL-6 induces the murine PEPCK 
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hslL-6R transgenic mice.  (A)  PEPCK/ 
hslL-6R  construct  injected into  fertil- 
ized mouse eggs. (B) Southern blot anal- 
ysis.  Genomic  tail  DNA  from  control 
mice and heterozygous (-/+)  and ho- 
mozygous (+/+) transgenic animals was 
digested  with  EcoRI  and  HindlII.  A 
32P-labeled  1.2-kb  XhoI-PstI-cDNA 
fragment was used for hybridization. (C) 
Expression  of  hslL-6R  mRNA  in 
PEPCK/hslL-6R transgenic mice. Total 
RNA (5 p,g), prepared from the liver of 
8-wk-old  control  mice  and  heterozy- 
gous  and  homozygous transgenic mice 
were subjected to Northern blot analysis and hybridized with a 32p-labeled 1.2-kb XlioI-Pstl-cDNA fragment.  (D)  hslL-6R was immunoprecipitated 
from mouse serum with the MT-18 antibody and subjected to Western blot analysis using a monospecific antiserum against hlL-6R. 
promoter and  drives  the  transcription  of hslL-6R,  RNA 
prepared  from  liver  tissue  from  homozygous  transgenic 
mice 4  h  after receiving different dosages  of human  IL-6 
was subjected to Northern blot analysis and was hybridized 
with a hslL-6R probe. Contemporaneously, blood was drawn 
from the mice, and the hslL-6R was immunoprecipitated 
with the monoclonal anti-IL-6R antibody MT18 and sub- 
jected to Western blot analysis. As can be seen from Fig. 2, 
different dosages ofhlL-6 did not lead to changes ofhslL-6R 
mRNA or protein expression. 
hslL-6R  Transgenic Mice  Are  Hypersensitized  towards the 
hlL-6-induced Acute Phase Protein Expression.  One major activ- 
ity of IL-6 is the induction of the hepatic acute phase re- 
sponse  (39).  We  therefore analyzed the  induction  of the 
acute phase protein gene expression by hlL-6 in the liver of 
hslL-6R  transgenic  mice.  Various  dosages  of hlL-6 were 
administered to the mice intraperitoneally, and mice were 
killed after 4 h  (Fig. 3). In the top panel of Fig.  3, the hap- 
toglobin mRNA  expression in control animals is demon- 
strated.  The strongest haptoglobin expression was seen when 
40 I~g hlL-6 was injected. In heterozygous hslL-6R trans- 
genic mice  (Fig.  3,  middle),  the strongest haptoglobin ex- 
pression was seen at a 10-fold lower dose (4 Ixg) compared 
to control animals.  In homozygous hslL-6R mice (Fig.  3, 
bottom), a hlL-6 dose of as low as 0.4 pog induced a signifi- 
cant  haptoglobin  mRNA  expression.  These  experiments 
clearly demonstrate that the hslL-6R renders transgenic mice 
more  sensitive  to  hlL-6  in  a  dose-dependent fashion.  In 
contrast,  when  control,  heterozygous,  and  homozygous 
hslL-6R  transgenic  animals  were  injected  with  8  p~g  of 
murine IL-6 and analyzed 4 h  after injection, an equal in- 
duction of the acute phase response was seen in all animals 
(data not shown). 
In  hslL-6R  Transgenic Mice  the  IL-6-induced Acute  Phase 
Protein Expression Is Markedly  Prolonged.  Time  course  ex- 
periments were performed with 8 Ixg hlL-6 injected intra- 
peritoneally (Fig. 4 A). In control mice (Fig.  4 A,  top), the 
strongest haptoglobin mRNA expression was detected after 
4 h, declined after 8 h, and was hardly detectable after 12 h. 
Figure  2.  Analysis of hslL-6R expression in  response to  IL-6.  Total 
RNA prepared from the liver of homozygous transgenic mice that re- 
ceived various dosages of human 1L-6 intraperitoneally, was subjected to 
Northern blot analysis  (top).  The hslL-6R was immunoprecipitated with 
the MT-18 antibody and subjected to Western blot analysis (bottom). 
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Figure 3.  Dose-response of  the hepatic acute phase protein expression. 
Haptoglobin  expression in  the liver of control mice  (-/-),  and  het- 
erozygous (-/+)  and homozygous (+/+)  transgenic mice was analyzed. 
Mice were injected intraperitoneally with various dosages ofhlL-6 as in- 
dicated. Mice were killed 4 h after injection and RNA was prepared from 
the liver and subjected to Northern blot analysis.  Filters were hybridized 
with a 32p-labeled  0.9-kb Hint restriction fragment of human haptoglo- 
bin cDNA. Figure 4.  Time course of the hepatic acute phase protein expression. Haptoglobin  expression in the liver of control mice (-/-),  and heterozygous 
(-/+) and homozygous (+/+) transgenic mice was analyzed. Mice were injected intraperitoneally with 8 p~g human IL-6 and killed after short- (A) or 
long-term (B) time periods as indicated.  RNA was prepared fi'om the liver and subjected to Northern blot analysis. Filters were  hybridized with a 
32p-labeled 0.9-kb Hinfl restriction fragment of human haptoglobin cDNA. 
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In heterozygous  hslL-6R  transgenic mice  (Fig.  4  A,  mid- 
dle),  the strongest haptoglobin mRNA  expression was  ob- 
served as soon as 2  h  after human IL-6 application and was 
detectable  throughout  the  experiment.  In  homozygous 
hslL-6R  mice  (Fig.  4,  bottom),  an increase  of haptoglobin 
expression was  seen 0.5  h  after IL-6 application and,  as in 
heterozygous mice, was more persistent. 
When  8  p~g hlL-6 was  given for longer periods  of time 
(Fig. 4  B)  to  control animals (top),  the strongest expression 
of haptoglobin was  seen after  8  h  and declined thereafter. 
In heterozygous  mice  (Fig.  4  B,  middle),  the  response was 
equally strong after  8  and  24  h;  in homozygous  hslL-6R 
mice (Fig. 4, bottom),  the expression of haptoglobin peaked 
at 24 h  and was still pronounced after 48 h  when compared 
to  control  animals (Fig.  4  B,  top) and heterozygous  trans- 
genic mice (Fig. 4 B, middle). 
slL-6R Functions as a Carrier Protein for IL-6 Prolonging the 
Serum Half-life  oflL-6.  To investigate the fate ofhlL-6 in- 
jected into IL-6R transgenic mice, we determined IL-6 se- 
rum levels using the hlL-6 ELISA (Fig. 5) and a murine B9 
Figure  5.  IL-6 serum levels. IL-6 serum levels in control  mice  (open 
bars), heterozygous (hatched  bars), and homozygous  (filled bars) transgenic 
mice were determined with a human IL-6 ELISA. (A) Dose-response ex- 
periments: mice were injected with various dosages of human IL-6 intra- 
peritoneaUy as indicated and were analyzed 4 h after injection.  (B) Time 
course experiments: mice were injected with 8 t~g hlL-6 intraperitoneally 
and were killed after indicated time periods. 
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IL-6 levels were  markedly elevated in  heterozygous,  and 
even higher in homozygous hslL-6R transgenic mice when 
compared to control animals (Fig.  5 A). In the time course 
experiment, there were also markedly higher IL-6 levels in 
hslL-6R transgenic mice compared to control mice (Fig.  5 
B).  IL-6 levels were undetectable  12 h  after application in 
control animals, but were still significantly elevated 20 h af- 
ter application in transgenic mice (Fig.  5 B).  Similar results 
were obtained when IL-6 levels were determined using the 
B9 assay (data not shown). 
Discussion 
To determine the role of the slL-6R in vivo, we made 
use of the species specificity ofhlL-6, which acts on human 
and murine IL-6R, in contrast to murine IL-6 which acts 
only  on  murine  IL-6R.  Transgenic  mice  expressing  the 
hslL-6R were generated, and the function of the hslL-6R 
was studied in vivo without the confounding action of en- 
dogenous murine IL-6. 
There  are  three  major findings  of this  study.  First,  the 
slL-6R makes animals more sensitive to the cytokine IL-6. 
According to studies performed in cell culture, the slL-6R 
renders  target cells  more sensitive and enables cells  to re- 
spond to IL-6 which by themselves do not bind the cytokine 
because  of lack  of surface  expression  of the  membrane- 
bound IL-6R (18,  30).  The degree of sensitization we ob- 
served in  the  transgenic  mice,  however,  exceeded by far 
the effect seen in cell culture: when hlL-6 was injected into 
hslL-6R  transgenic  animals and  the  IL-6-mediated acute 
phase proteine  expression was measured, these mice were 
found to be  10--100-fold more sensitive towards hlL-6 as 
compared to control animals.  In contrast,  the injection of 
murine IL-6 did not result in an increased acute phase pro- 
tein  expression  in  hslL-6R  transgenic  mice  when  com- 
pared to control animals. This finding confirms the species 
specificity of murine IL-6, which has no effect on human 
target cells and argues against any interference of endoge- 
nous murine IL-6 with the hslL-6R. Since the acute phase 
response induced by murine IL-6 was equal in control, het- 
erozygous,  and  homozygous hslL-6R  transgenic  animals, 
one can conclude that the binding of hlL-6 to membrane- 
bound and soluble murine IL-6 receptor does not contrib- 
ute  to  the  dose-dependent,  IL-6-induced  hypersensitiza- 
tion  of  hslL-6R  transgenic  mice  demonstrated  in  our 
study.  Second,  time  course  experiments  revealed  that  in 
hslL-6R transgenic animals, the IL-6-mediated acute phase 
response persisted much longer as compared with  control 
animals.  In  homozygous  hslL-6R  transgenic  mice,  the 
acute  phase  response persisted  as  long as  48  h.  Third,  in 
hslL-6R  transgenic  animals,  the  IL-6  serum  levels  are 
markedly elevated and the plasma half-life of IL-6 is signifi- 
cantly  prolonged.  In  a  dose-dependent  fashion,  hslL-6R 
transgenic mice have two- to three-fold higher IL-6 serum 
levels as compared to  control animals.  Moreover, in time 
course  experiments  (Fig.  5)  IL-6 levels are  detectable for 
20 h  in  hslL-6R  transgenic  animals,  whereas  in  control 
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mice, IL-6 levels could be measured for only 12 h. It is in- 
teresting that the IL-6 plasma levels are detectable longer in 
heterozygous  hslL-6R  transgenic  mice  than  in  homozy- 
gous  mice  (Fig.  5  B).  This  effect becomes apparent  after 
4 h. One could argue that this represents a contradiction to 
the finding that in homozygous mice the  acute phase re- 
sponse persists longer than in heterozygous mice (Fig. 4 B). 
It is likely that there is an increased retention of the IL-6/ 
IL-6R complex in the circulation resulting in a prolonga- 
tion of the half-life due to the increased size and stability of 
the  complex.  Moreover,  it is  well  known  that  the  IL-6/ 
IL-6R  complex  is  internalized  after  activation  of mem- 
brane-bound gpl30  (40,  41).  It is possible that the  clear- 
ance of IL-6 and thus the IL-6 levels in vivo, are determined 
by an equilibrium between retention and internalization of 
the  IL-6/IL-6R  complex,  which  in  the  case  of higher 
IL-6R levels, as measured in homozygous hslL-6R mice, is 
shifted towards internalization. This notion is supported by 
data  from patients  with  sepsis,  in  whom  highly increased 
IL-6 levels and  significandy  decreased  slL-6R  levels were 
measured when compared with control patients (42). 
Cytokine  receptors  are  important  in  the  regulation  of 
cytokines and growth factors. There are multiple ways to 
regulate receptor function:  (a) expression of receptors may 
be restricted to specific cell types; (b) the receptor number 
on  the  plasma  membrane  may  vary because  of receptor 
mRNA  regulation  or receptor internalization;  (c)  the  re- 
ceptor affinities may be modulated on some cells by addi- 
tional  membrane  proteins  that  interact  with  the  ligand- 
binding protein; or (d) the membrane-bound receptor may 
be transformed into  a  soluble form by limited proteolysis 
(28).  Not only cytokines have soluble counterparts, but also 
other transmembrane proteins, such as adhesion molecules 
(intercellular  adhesion  molecule  1)  (43),  the  LPS-binding 
protein CD14 (44),  and the B and T  cell membrane glyco- 
proteins CD27 and CD40 (45).  Soluble receptors for most 
cytokines have been detected in many human body fluids, 
the majority inhibiting the function of their respective ligands. 
The slL-6R has been demonstrated to act agonisticaUy on 
cells  bearing  gp130  molecules  on  their  surface  if IL-6 is 
present.  IL-6 serum levels detected  in  normal individuals 
are very low.  It is noteworthy that at such concentrations 
there is litde or no responsiveness to this cytokine. In the 
presence  of  the  slL-6R,  however,  such  concentrations 
could stimulate target cells. 
We have recently shown that melanoma cells transfected 
with the murine slL-6R, when injected into syngeneic mice, 
are  much  less  effective in  tumor  induction  or  metastasis 
formation compared to untransfected melanoma cells  (46, 
47). In this situation the sensitivity towards the endogenous 
murine IL-6 seems to be amplified by the presence of the 
slL-6R protein. 
The biological importance of the shedding process as a 
major mechanism of generating soluble proteins is protean: 
(a) growth factors or cytokines are liberated such as TNF-a, 
TGF-a, and kit ligand;  (b) soluble receptors are generated 
and  act as  competitors of the  membrane-bound counter- 
parts and thereby antagonize the cytokine response; and (c) for receptors  of the  IL-6 family  (formally  shown  for the 
IL-6R and the receptor for the ciliary neurotrophic factor) 
and for the LPS receptor CD14,  it has been demonstrated 
that the soluble proteins act as agonists,  i.e.,  together with 
their  ligands  they  are  able  to  induce  signaling  on  cells 
which by themselves  are unresponsive  to the ligand.  This 
process has recently been termed transsignaling (28). There 
is an increasing number of reports on cells being responsive 
to  IL-6 only when  IL-6R is  present:  bone  resorption  in 
vivo  and  in  the  osteoblast/osteoclast  coculture  (48-50), 
CD34 §  stem  cell proliferation  (51),  and  the  induction  of 
alveolitis  (52)  are  markedly  enhanced  in  the  presence  of 
both IL-6 and IL-6R as compared to stimulation with IL-6 
alone.  In this  context,  generation  of slL-6R not only has 
the  effect of sensitization  and  prolongation,  but  also  of a 
change of quality of the response. We were able to demon- 
strate  that  the  phorbol  ester  PMA  induces  quantitative 
shedding of the slL-6R, indicating that protein kinase C  is 
involved in this process  (22,  53).  Most recently,  we  have 
shown  that  not  only  PMA,  but  also  LPS  markedly  en- 
hances shedding  (54),  indicating  that increased generation 
of  the  slL-6R  might  occur  during  bacterial  infections. 
Based on these findings, it will be important to elucidate the 
mechanism responsible for the generation of soluble recep- 
tor proteins. 
In the future, it will be interesting to study the status of 
the slL-6R during inflammatory and infectious conditions. 
This might change our view of the function oflL-6 in var- 
ious pathophysiological states.  Moreover,  the  IL-6/IL-6R 
complex, and not IL-6 alone, might be regarded as the ac- 
tive  cytokine in vivo.  To  further  address  this  question,  it 
will be interesting to generate double transgenic mice,  ex- 
pressing hlL-6 in conjunction with the shlL-6R. 
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